[Age-related macular degeneration: therapeutic hopes]

Med Sci (Paris). 2007 Feb;23(2):127-9. doi: 10.1051/medsci/2007232127.
[Article in French]
No abstract available

Publication types

  • News

MeSH terms

  • Age of Onset
  • Aged
  • Aged, 80 and over
  • Aging
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Aptamers, Nucleotide / pharmacology
  • Aptamers, Nucleotide / therapeutic use
  • Bevacizumab
  • Double-Blind Method
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Macular Degeneration / drug therapy*
  • Macular Degeneration / epidemiology
  • Macular Degeneration / genetics
  • Male
  • Middle Aged
  • Multicenter Studies as Topic
  • Randomized Controlled Trials as Topic
  • Ranibizumab
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vascular Endothelial Growth Factor A / immunology

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Aptamers, Nucleotide
  • Vascular Endothelial Growth Factor A
  • pegaptanib
  • Bevacizumab
  • Ranibizumab